FDA selects Merck, IBM, KPMG and Walmart for blockchain pilot
17-06-2019
Boehringer teams up with Gubra to develop second obesity treatment
30-05-2019
IBM patent targets blockchain in open scientific research
14-11-2018
laborant / Shutterstock.com
The Canadian units of IBM and pharmaceutical company Boehringer Ingelheim have united to explore the use of blockchain technology in clinical trials.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Boehringer Ingelheim, IBM, blockchain, blockchain technology, clinical trials, patient safety
